- Product Pipeline Review - H2 2011” provides a detailed overview on the BioDelivery Sciences International, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industries Direct’s proprietary databases, BioDelivery Sciences International, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from BioDelivery Sciences International, Inc. and market -specific third party sources, put together by Global Industries Direct’s team.

Scope of the Research

- BioDelivery Sciences International, Inc. - Brief BioDelivery Sciences International, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of BioDelivery Sciences International, Inc. human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of BioDelivery Sciences International, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the BioDelivery Sciences International, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate BioDelivery Sciences International, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of BioDelivery Sciences International, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the BioDelivery Sciences International, Inc.’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with BioDelivery Sciences International, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of BioDelivery Sciences International, Inc. and identify potential opportunities in those areas.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
BioDelivery Sciences International, Inc. Snapshot 7
BioDelivery Sciences International, Inc. Overview 7
Key Information 7
Key Facts 7
BioDelivery Sciences International, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
BioDelivery Sciences International, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
BioDelivery Sciences International, Inc. - Pipeline Products Glance 12
BioDelivery Sciences International, Inc. - Late Stage Pipeline 12
Registration Filed Products/Combination Treatment Modalities 12
Phase III Products/Combination Treatment Modalities 13
BioDelivery Sciences International, Inc. Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
BioDelivery Sciences International, Inc. - Early Stage Pipeline Products 16
Discovery Products/Combination Treatment Modalities 16
BioDelivery Sciences International, Inc. - Drug Profiles 17
BEMA Buprenorphine 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
BEMA Granisetron 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
BEMA Triptan 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Bioral Amphotericin B 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
ONSOLIS 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
BioDelivery Sciences International, Inc. - Pipeline Analysis 22
BioDelivery Sciences International, Inc. - Pipeline Products by Therapeutic Class 22
BioDelivery Sciences International, Inc. - Pipeline Products By Target 24
BioDelivery Sciences International, Inc. - Pipeline Products by Route of Administration 25
BioDelivery Sciences International, Inc. - Pipeline Products by Molecule Type 26
BioDelivery Sciences International, Inc. - Recent Pipeline Updates 27
BioDelivery Sciences International, Inc. - Dormant Projects 29
BioDelivery Sciences International, Inc. - Firms Statement 30
BioDelivery Sciences International, Inc. - Locations And Subsidiaries 34
Head Office 34
Other Locations and Subsidiaries 34
Company's Recent Developments 36
BioDelivery Sciences International, Inc., Recent Developments 36
August 30, 2010: BioDelivery Sciences Reports BEMA Buprenorphine Phase II Study Results Selected For Presentation At Pain Week 2010 36
September 28, 2011: BioDelivery Sciences Announces Results From Phase III Efficacy Study For BEMA Buprenorphine In Chronic Pain 36
June 28, 2007: BioDelivery Sciences Initiates Bioral Amphotericin B Clinical Program 37
October 27, 2010: BioDelivery Sciences Reports Positive End-Of-Phase II Meeting With FDA For BEMA Buprenorphine In Chronic Pain 38
July 25, 2011: BioDelivery Sciences Announces Completion Of BEMA Buprenorphine Phase III Chronic Pain Study 38
March 23, 2010: BioDelivery Sciences Announces Positive Pre-IND Meeting On BEMA Granisetron Development Program 39
August 22, 2011: BioDelivery Sciences Announces Commercial Launch Of ONSOLIS In Canada 40
December 17, 2009: BioDelivery Sciences Announces Positive Phase II Trial Results Of BEMA Buprenorphine For The Treatment Of Dental Surgery 40
July 17, 2009: Onsolis received FDA approval. 41
February 17, 2011: BioDelivery Sciences Provides Update On BEMA Buprenorphine Phase III Chronic Pain Study 41
January 12, 2010: BDSI To Discuss Planned BEMA Granisetron IND With The FDA 42
November 10, 2011: BioDelivery Sciences Initiates Confirmatory Pharmacokinetic Study Of BEMA Buprenorphine/Naloxone Compared To Suboxone 42
December 09, 2010: BioDelivery Sciences Begins Phase III BEMA Buprenorphine Clinical Program For Treatment Of Chronic Pain 43
November 07, 2011: TTY Biopharm Submits March keting Authorization For BEMA Fentanyl In Taiwan 44
September 06, 2011: BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation For Opioid Dependence 44
April 05, 2011: BioDelivery Sciences Completes Recruitment In BEMA Buprenorphine Phase III Chronic Pain Study 45
February 05, 2009: BioDelivery Sciences Announces Initial Results Of Phase I Clinical Study Of Bioral Amphotericin B 45
September 02, 2010: BioDelivery Sciences Announces Positive Meeting With FDA On ONSOLIS REMS With Broadened Distribution 46
March 02, 2011: BioDelivery Sciences Confirms 505(b)(2) Pathway For BEMA Buprenorphine/Naloxone For Opioid Dependence Following FDA Meeting 46
Financial Deals Landscape 48
BioDelivery Sciences International, Inc., Deals Summary 48
BioDelivery Sciences International, Inc., Pharmaceuticals and Healthcare, Deal Details 50
Asset Transactions 50
BioDelivery Sciences Takes Over Rights To The BEMA Drug Delivery Technology From QLT USA 50
BioDelivery Sciences International Takes Over BEMA Drug Delivery Technology From QLT 52
Partnerships 54
BioDelivery Sciences Amends Co-March keting Agreement With Meda 54
BioDelivery Sciences Expands Co-Development Agreement With Meda 56
Biodelivery Sciences International Concludes a New Deal With Meda 58
Licensing Agreements 60
BioDelivery Sciences Enters Into Licensing Agreement With TTY Biopharm Firms 60
BioDelivery Sciences Enters Into Licensing Agreement With Kunwha Pharmaceutical 62
Biodelivery Sciences International Enters Into Licensing Agreement With Meda 63
BioDelivery Sciences International Enters Into License Agreement With Clinical Development Capital 65
BioDelivery Sciences International Enters Into Licensing Agreement With Sigma-Tau 66
Atrix Laboratories Enters Into Licensing Agreement With Arius Pharmaceuticals 67
Accentia BioPharmaceuticals Enters Into Licensing Agreement With BioDelivery Sciences International 68
Equity Offering 69
BioDelivery Sciences International Completes Private Placement Of US$ 15 Mln 69
BioDelivery Sciences International Completes Registered Direct Offering Of US$ 10 Mln 71
BioDelivery Sciences Completes Public Offering Of US$ 8.91 Mln 73
Debt Offering 75
BioDelivery Sciences Completes Private Placement Of US$ 2.5 Mln Secured Convertible Note 75
BioDelivery Sciences Completes Private Placement Of Secured Notes For US$ 2.5 million 77
Asset Transactions 79
Meda Takes Over Rights Of Onsolis From BioDelivery Sciences International 79
Accentia Biopharmaceuticals Takes Over 50% Royalty Of encochleated Amphotericin B From BioDelivery Sciences 81
Acquisition 83
BioDelivery Sciences International Takes Over Arius Pharmaceuticals 83
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 86
Expert Panel Validation 86
Contact Us 86
Disclaimer 86

List of Tables

BioDelivery Sciences International, Inc., Facts and Figures 7
BioDelivery Sciences International, Inc., Key Facts 7
BioDelivery Sciences International, Inc. - Pipeline by Therapy Area and Indication, H2 2011 9
BioDelivery Sciences International, Inc. - Pipeline by Stage of Development, H2 2011 10
BioDelivery Sciences International, Inc. - Monotherapy Products in Pipeline, H2 2011 11
BioDelivery Sciences International, Inc. - Filed, H2 2011 12
BioDelivery Sciences International, Inc. - Phase III, H2 2011 13
BioDelivery Sciences International, Inc. - Phase II, H2 2011 14
BioDelivery Sciences International, Inc. - Phase I, H2 2011 15
BioDelivery Sciences International, Inc. - Discovery, H2 2011 16
BioDelivery Sciences International, Inc. - Pipeline By Therapeutic Class, H2 2011 23
BioDelivery Sciences International, Inc. - Pipeline By Target, H2 2011 24
BioDelivery Sciences International, Inc. - Pipeline By Route of Administration, H2 2011 25
BioDelivery Sciences International, Inc. - Pipeline By Molecule Type, H2 2011 26
BioDelivery Sciences International, Inc. - Recent Pipeline Updates, H2 2011 27
BioDelivery Sciences International, Inc. - Dormant Developmental Projects, 2010 29
BioDelivery Sciences International, Inc., Other Locations 34
BioDelivery Sciences International, Inc., Subsidiaries 35
BioDelivery Sciences International, Inc., Deals Summary 48
BioDelivery Sciences Takes Over Rights To The BEMA Drug Delivery Technology From QLT USA 50
BioDelivery Sciences International Takes Over BEMA Drug Delivery Technology From QLT 52
BioDelivery Sciences Amends Co-March keting Agreement With Meda 54
BioDelivery Sciences Expands Co-Development Agreement With Meda 56
Biodelivery Sciences International Concludes a New Deal With Meda 58
BioDelivery Sciences Enters Into Licensing Agreement With TTY Biopharm Firms 60
BioDelivery Sciences Enters Into Licensing Agreement With Kunwha Pharmaceutical 62
Biodelivery Sciences International Enters Into Licensing Agreement With Meda 63
BioDelivery Sciences International Enters Into License Agreement With Clinical Development Capital 65
BioDelivery Sciences International Enters Into Licensing Agreement With Sigma-Tau 66
Atrix Laboratories Enters Into Licensing Agreement With Arius Pharmaceuticals 67
Accentia BioPharmaceuticals Enters Into Licensing Agreement With BioDelivery Sciences International 68
BioDelivery Sciences International Completes Private Placement Of US$ 15 Mln 69
BioDelivery Sciences International Completes Registered Direct Offering Of US$ 10 Mln 71
BioDelivery Sciences Completes Public Offering Of US$ 8.91 Mln 73
BioDelivery Sciences Completes Private Placement Of US$ 2.5 Mln Secured Convertible Note 75
BioDelivery Sciences Completes Private Placement Of Secured Notes For US$ 2.5 million 77
Meda Takes Over Rights Of Onsolis From BioDelivery Sciences International 79
Accentia Biopharmaceuticals Takes Over 50% Royalty Of encochleated Amphotericin B From BioDelivery Sciences 81
BioDelivery Sciences International Takes Over Arius Pharmaceuticals 83

List of Figures

BioDelivery Sciences International, Inc. - Pipeline by Therapy Area and Indication, H2 2011 9
BioDelivery Sciences International, Inc. - Pipeline by Stage of Development, H2 2011 10
BioDelivery Sciences International, Inc. - Monotherapy Products in Pipeline, H2 2011 11
BioDelivery Sciences International, Inc. - Pipeline By Therapeutic Class, H2 2011 22
BioDelivery Sciences International, Inc. - Pipeline By Target, H2 2011 24
BioDelivery Sciences International, Inc. - Pipeline By Route of Administration, H2 2011 25

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2014

Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2014

  • $ 2 000
  • Company report
  • June 2014
  • by Global Markets Direct

Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2014', provides an overview of the Dry (Atrophic) ...

Emesis (Vomiting) - Pipeline Review, H1 2014

Emesis (Vomiting) - Pipeline Review, H1 2014

  • $ 2 000
  • Company report
  • June 2014
  • by Global Markets Direct

Emesis (Vomiting) - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Emesis (Vomiting) - Pipeline Review, H1 2014', provides an overview of the Emesis (Vomiting)'s therapeutic pipeline. This ...

Fragile X Syndrome - Pipeline Review, H1 2014

Fragile X Syndrome - Pipeline Review, H1 2014

  • $ 2 000
  • Company report
  • June 2014
  • by Global Markets Direct

Fragile X Syndrome - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Fragile X Syndrome - Pipeline Review, H1 2014', provides an overview of the Fragile X Syndrome's therapeutic pipeline. ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.